2022

1. Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity

   Human Genetics, Vol. 141, Núm. 1, pp. 147-173

2. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

   The Lancet Infectious Diseases, Vol. 22, Núm. 3, pp. 329-340